Original Source(s)
Related Content
FDA approves new pertuzumab biosimilar
Approved for metastatic and early-stage breast cancer, the biosimilar cannot launch in the US before Q3 2028.
by Mouj Hijazi
November 17, 2026
-
2 min
FDA approves first NPC survival treatment
Median survival reached 8.5 vs 4.9 years in patients with infantile-onset Niemann-Pick disease type C.
by Mouj Hijazi
November 18, 2026
-
2 min